Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of “Moderate Buy” from Analysts

Oncolytics Biotech Inc. (NASDAQ:ONCY) has been given an average rating of “Moderate Buy” by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $8.50.

A number of equities analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Friday, March 27th. Wall Street Zen raised Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research report on Saturday.

Insider Transactions at Oncolytics Biotech

In other news, Director Bernd R. Seizinger acquired 40,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was purchased at an average price of $0.85 per share, for a total transaction of $34,000.00. Following the completion of the acquisition, the director directly owned 566,991 shares in the company, valued at $481,942.35. The trade was a 7.59% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Wayne Pisano acquired 30,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were purchased at an average price of $0.84 per share, with a total value of $25,200.00. Following the acquisition, the director owned 492,414 shares of the company’s stock, valued at approximately $413,627.76. This represents a 6.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 404,282 shares of company stock worth $363,232. 0.10% of the stock is currently owned by insiders.

Institutional Trading of Oncolytics Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new position in shares of Oncolytics Biotech in the third quarter valued at $535,000. Scientech Research LLC acquired a new position in shares of Oncolytics Biotech during the third quarter valued at about $25,000. Ground Swell Capital LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter valued at about $30,000. CIBC Private Wealth Group LLC bought a new stake in shares of Oncolytics Biotech during the fourth quarter worth about $44,000. Finally, Tocqueville Asset Management L.P. bought a new stake in shares of Oncolytics Biotech during the fourth quarter worth about $63,000. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at $0.96 on Monday. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.51. The firm’s fifty day moving average is $0.98 and its 200 day moving average is $1.05. The company has a market capitalization of $111.52 million, a PE ratio of -3.31 and a beta of 0.98.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Sell-side analysts expect that Oncolytics Biotech will post -0.28 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.